SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02070536

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Predictive Values of Plasma Soluble RAGE Levels and RAGE Polymorphisms for the Onset of Acute Respiratory Distress Syndrome in Critically Ill Patients

Current clinical prediction scores for acute respiratory distress syndrome (ARDS) have limited positive predictive value. No studies have evaluated predictive kinetics of plasma biomarkers and receptor for advanced glycation end products (RAGE) polymorphisms in a broad population of critically ill patients or as an adjunct to clinical prediction scores. The main objective of the investigators study is to evaluate the predictive values of plasma soluble RAGE levels for the onset of ARDS in a high risk population of patients admitted to the intensive care unit (ICU). One of the investigators goals is to improve early identification of patients at risk for ARDS in order to better implement preventive stategies prior to ARDS development. The primary outcome is the occurrence of ARDS during the first week after admission to the ICU.

NCT02070536 Intensive Care Unit Population at High Risk for ARDS Development
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

1 Interventions

Name: sRAGE

Type: Other
Group Labels: 1

ARDS (Acute Respiratory Distress Syndrome)


Primary Outcomes

Description: The development of ARDS, based on Berlin definition criteria, during the first week after admission to the ICU

Measure: development of ARDS

Time: during the first week after admission to the ICU

Secondary Outcomes

Measure: Plasma sRAGE and esRAGE levels

Time: at ICU admission (Day 0)

Measure: Plasma sRAGE and esRAGE levels

Time: (Day 1)

Measure: Evolution of plasma sRAGE levels

Time: between day 0 and day 1

Measure: Maximal plasma levels of sRAGE and esRAGE

Time: during the first 24 hours after ICU admission

Measure: Development of ARDS

Time: during at day 14 and day 30 after ICU admission

Measure: Total duration of mechanical ventilation

Time: at day 1

Measure: Length of stay in ICU

Time: at day 1

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 G82S

The secondary objectives are to : - to evaluate the predictive value of RAGE polymorphisms (_429 T/C, _374 T/A, 2184 A/G, Gly82Ser) for the onset of ARDS - to evaluate the predictive value of maximal plasma levels of RAGE soluble forms for the onset of ARDS - to test the relationship between RAGE polymorphisms and plasma sRAGE and esRAGE levels - to test whether serial sRAGE measurements would improve the discrimination of the LIP Score or not - to evaluate the prognostic value of plasma levels of RAGE soluble forms for : duration of mechanical ventilation, length of stay in the ICU and 30-day mortality. --- Gly82Ser ---



HPO Nodes